About this episode
Hello Subs! This (long) podcast covers OCUL’s AXPAXLI vs. EYPT’s DURAVYU ahead of the readout of EYPT’s first-phase 3 study called LUGANO. I provide background on the science, clinical data, endpoints we know (from OCUL’s SOL-1), and endpoints we’re extrapolating based on existing data (to OCUL’s SOL-R and EYPT’s LUGANO/LUCIA studies). I make some predictions and share my assessment of the market. I conclude with thoughts on valuation and how my portfolio is positioned at this time. Cheers! JNap Disclosure: We are Long OCUL, Short EYPT This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit bio5c.substack.com/subscribe
Comments
Rate this episode
Episode Details
- Author
- JNap
- Show Type
- full
- Audio Format
- audio/mpeg
